NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Capital Reinvestment Ratio

Latest as of December 2022: 0.00x

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Capital Reinvestment Ratio of 0.00x as of December 2022, meaning it reinvests 0% of its operating cash flow ($29.19 Million) in capital expenditures ($109.43K). Check NAMS tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$29.19 Million
USD

Capital Expenditures

$109.43K
USD

Data as of

Dec 2022
Most recent filing

NewAmsterdam Pharma Company N.V. Ordinary Shares Capital Reinvestment Ratio (2022–2022)

This chart tracks NewAmsterdam Pharma Company N.V. Ordinary Shares's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see NAMS operating cash flow.

Annual Capital Reinvestment Ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares (2022–2022)

Year-by-year Capital Reinvestment Ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares from 2022 to 2022. See cash generation quality of NewAmsterdam Pharma Company N.V. Ordinar to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2022 0.02x $10.66 Million $221.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow